Please use this identifier to cite or link to this item:
https://doi.org/10.1038/bmt.2010.14
DC Field | Value | |
---|---|---|
dc.title | The role of allogeneic SCT in primary myelofibrosis: A British Society for Blood and Marrow Transplantation study | |
dc.contributor.author | Stewart, W.A. | |
dc.contributor.author | Pearce, R. | |
dc.contributor.author | Kirkland, K.E. | |
dc.contributor.author | Bloor, A. | |
dc.contributor.author | Thomson, K. | |
dc.contributor.author | Apperley, J. | |
dc.contributor.author | McQuaker, G. | |
dc.contributor.author | Marks, D.I. | |
dc.contributor.author | Craddock, C. | |
dc.contributor.author | McCann, S. | |
dc.contributor.author | Russell, N. | |
dc.contributor.author | Cook, G. | |
dc.contributor.author | Kottaridis, P.D. | |
dc.date.accessioned | 2016-09-01T07:17:14Z | |
dc.date.available | 2016-09-01T07:17:14Z | |
dc.date.issued | 2010-11-07 | |
dc.identifier.citation | Stewart, W.A., Pearce, R., Kirkland, K.E., Bloor, A., Thomson, K., Apperley, J., McQuaker, G., Marks, D.I., Craddock, C., McCann, S., Russell, N., Cook, G., Kottaridis, P.D. (2010-11-07). The role of allogeneic SCT in primary myelofibrosis: A British Society for Blood and Marrow Transplantation study. Bone Marrow Transplantation 45 (11) : 1587-1593. ScholarBank@NUS Repository. https://doi.org/10.1038/bmt.2010.14 | |
dc.identifier.issn | 02683369 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/126292 | |
dc.description.abstract | Fifty-one patients with primary myelofibrosis (PMF) received allogeneic haematopoietic stem cell transplants from related (n=33) or unrelated (n=18) donors. Twenty-seven patients, 19-54 years old, were prepared with myeloablative regimens including CY plus BU (n=4) or TBI (n=23). Twenty-four patients, 40-64 years old, received reduced-intensity conditioning (RIC) regimens. All RIC regimens contained fludarabine, combined with melphalan (n=19) or BU (n=5), and alemtuzumab or anti-thymocyte globulin (ATG) in the majority (n=19). Four patients (17%) in the RIC group had primary graft failure. Previous splenectomy reduced time to engraftment in the RIC group (13 versus 20 days; P=0.008). For MA and RIC groups, respectively, at 3 years, overall survival rates were 44 and 31% (P=0.67), progressionfree survival 44 and 24% (P=0.87), and actuarial relapse rates 15 and 46% (P=0.06). Non-relapse mortality at 3 years was 41% for the myeloablative and 32% for the RIC group. Acute GVHD occurred in 29 and 38% of patients in the myeloablative and RIC groups, respectively. Extensive chronic GVHD developed in 30 and 35% of evaluable patients, respectively. © 2010 Macmillan Publishers Limited. All rights reserved. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1038/bmt.2010.14 | |
dc.source | Scopus | |
dc.subject | myeloablative conditioning regimens | |
dc.subject | myelofibrosis | |
dc.subject | reduced-intensity conditioning regimens | |
dc.subject | SCT | |
dc.type | Article | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.description.doi | 10.1038/bmt.2010.14 | |
dc.description.sourcetitle | Bone Marrow Transplantation | |
dc.description.volume | 45 | |
dc.description.issue | 11 | |
dc.description.page | 1587-1593 | |
dc.description.coden | BMTRE | |
dc.identifier.isiut | 000284063500002 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.